Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588600076> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2588600076 abstract "Background The pharmacovigilance of medical products for human use should start during the clinical development and continues after licensure. In developed countries, regulatory agencies are actively involved in all steps of pharmacovigilance. In sub-Saharan African countries, the lack and weaknesses of national regulatory authorities are being addressed through regional regulatory authorities like AVAREF 2 which aims to oversee pharmacovigilance duties across countries. Informing such initiative about the current practices for the reporting of serious adverse events is needed. Methods We reviewed the reporting of clinical trials performed in CERMEL from 2006–2016. The methods of serious adverse events (SAE) reporting and handling was the main objective of the review. Results The most frequent methods used to reporting SAE for the clinical trials reviewed in Lambarene were: 31% (5/16) paper Case Report Forms (CRF) only, 25% (4/16) electronic case report form (eCRF) without alert, 13% ( 2/16) paper CRF+phone call and 13% (2/16) phone +email or fax+ paper CRF and 6% (1/16) electronic SAE reporting system with alert. Generally, all studies reported SAEs directly to the sponsors who reacted according to their guidelines. Only 2 of 16 studies could involve the Institutional Review Board (IRB), Ethics Committees, and the Data Safety Monitoring Committee (DSMC) and eventually reported to the Regulatory Authorities in the country. The Local Safety Monitoring was involved only in one study which used the eCRF with alert. Conclusions It appears that in the current practices, the reporting and handling of SAEs are mainly done by investigators and sponsors. Although both are the key stakeholders to do so, more active involvement of regulatory authorities is an essential step towards establishment of a pharmacovigilance system and would improve the community engagement towards clinical trials. Electronic reporting with alert system could be one of the methods suitable to involve all partners." @default.
- W2588600076 created "2017-02-24" @default.
- W2588600076 creator A5048242735 @default.
- W2588600076 creator A5055729744 @default.
- W2588600076 date "2017-02-01" @default.
- W2588600076 modified "2023-09-28" @default.
- W2588600076 title "INVOLVEMENT OF STAKEHOLDERS IN THE REPORTING PROCESS OF SERIOUS ADVERSE EVENTS DURING CLINICAL TRIALS IN A SUB-SAHARAN RESEARCH CENTER, LAMBARÉNÉ, GABON" @default.
- W2588600076 doi "https://doi.org/10.1136/bmjgh-2016-000260.169" @default.
- W2588600076 hasPublicationYear "2017" @default.
- W2588600076 type Work @default.
- W2588600076 sameAs 2588600076 @default.
- W2588600076 citedByCount "0" @default.
- W2588600076 crossrefType "journal-article" @default.
- W2588600076 hasAuthorship W2588600076A5048242735 @default.
- W2588600076 hasAuthorship W2588600076A5055729744 @default.
- W2588600076 hasBestOaLocation W25886000761 @default.
- W2588600076 hasConcept C138885662 @default.
- W2588600076 hasConcept C142724271 @default.
- W2588600076 hasConcept C144133560 @default.
- W2588600076 hasConcept C17744445 @default.
- W2588600076 hasConcept C197934379 @default.
- W2588600076 hasConcept C199539241 @default.
- W2588600076 hasConcept C2778707766 @default.
- W2588600076 hasConcept C2781342390 @default.
- W2588600076 hasConcept C41895202 @default.
- W2588600076 hasConcept C512399662 @default.
- W2588600076 hasConcept C535046627 @default.
- W2588600076 hasConcept C545542383 @default.
- W2588600076 hasConcept C57658597 @default.
- W2588600076 hasConcept C71924100 @default.
- W2588600076 hasConcept C98274493 @default.
- W2588600076 hasConceptScore W2588600076C138885662 @default.
- W2588600076 hasConceptScore W2588600076C142724271 @default.
- W2588600076 hasConceptScore W2588600076C144133560 @default.
- W2588600076 hasConceptScore W2588600076C17744445 @default.
- W2588600076 hasConceptScore W2588600076C197934379 @default.
- W2588600076 hasConceptScore W2588600076C199539241 @default.
- W2588600076 hasConceptScore W2588600076C2778707766 @default.
- W2588600076 hasConceptScore W2588600076C2781342390 @default.
- W2588600076 hasConceptScore W2588600076C41895202 @default.
- W2588600076 hasConceptScore W2588600076C512399662 @default.
- W2588600076 hasConceptScore W2588600076C535046627 @default.
- W2588600076 hasConceptScore W2588600076C545542383 @default.
- W2588600076 hasConceptScore W2588600076C57658597 @default.
- W2588600076 hasConceptScore W2588600076C71924100 @default.
- W2588600076 hasConceptScore W2588600076C98274493 @default.
- W2588600076 hasLocation W25886000761 @default.
- W2588600076 hasOpenAccess W2588600076 @default.
- W2588600076 hasPrimaryLocation W25886000761 @default.
- W2588600076 hasRelatedWork W2004985771 @default.
- W2588600076 hasRelatedWork W2015255094 @default.
- W2588600076 hasRelatedWork W2021778357 @default.
- W2588600076 hasRelatedWork W2036761550 @default.
- W2588600076 hasRelatedWork W2049991395 @default.
- W2588600076 hasRelatedWork W2084391324 @default.
- W2588600076 hasRelatedWork W2114984525 @default.
- W2588600076 hasRelatedWork W2121995444 @default.
- W2588600076 hasRelatedWork W2169559966 @default.
- W2588600076 hasRelatedWork W2325071478 @default.
- W2588600076 hasRelatedWork W2399361352 @default.
- W2588600076 hasRelatedWork W2403398910 @default.
- W2588600076 hasRelatedWork W2407698879 @default.
- W2588600076 hasRelatedWork W2410757192 @default.
- W2588600076 hasRelatedWork W2412053919 @default.
- W2588600076 hasRelatedWork W2529917995 @default.
- W2588600076 hasRelatedWork W2915418787 @default.
- W2588600076 hasRelatedWork W3111781224 @default.
- W2588600076 hasRelatedWork W3138710583 @default.
- W2588600076 hasRelatedWork W331418554 @default.
- W2588600076 isParatext "false" @default.
- W2588600076 isRetracted "false" @default.
- W2588600076 magId "2588600076" @default.
- W2588600076 workType "article" @default.